NovoCure Limited - Ordinary Shares (NVCR): Price and Financial Metrics
NovoCure Limited - Ordinary Shares (NVCR)
Today's Latest Price: $167.55 USD
Updated Jan 15 4:00pm
Add NVCR to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 239 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
NVCR Stock Summary
- NVCR's current price/earnings ratio is 951.16, which is higher than 98.86% of US stocks with positive earnings.
- Price to trailing twelve month operating cash flow for NVCR is currently 346.11, higher than 98.82% of US stocks with positive operating cash flow.
- Over the past twelve months, NVCR has reported earnings growth of -2,119.91%, putting it ahead of merely 1.03% of US stocks in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to NovoCure Ltd are NUAN, GORO, KTOS, CELH, and PGNY.
- To check out NovoCure Ltd's SEC filings, go to the company's page on browse-edgar?action=getcompany&CIK=0001645113.
NVCR Stock Price Chart Interactive Chart >
NVCR Price/Volume Stats
| Current price | $167.55 | 52-week high | $182.74 |
| Prev. close | $178.94 | 52-week low | $53.40 |
| Day low | $167.41 | Volume | 923,200 |
| Day high | $179.69 | Avg. volume | 750,530 |
| 50-day MA | $148.80 | Dividend yield | N/A |
| 200-day MA | $98.20 | Market Cap | 17.06B |
NovoCure Limited - Ordinary Shares (NVCR) Company Bio
NovoCure Limited is a commercial stage oncology company which develops treatment for solid tumor cancers therapy called the tumor treating fields. The company was founded in 2000 and is based in Saint Helier, Channel Islands.
NVCR Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $167.55 | $7493.63 | 4088% |
Below please find a table outlining a discounted cash flow forecast for NVCR, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that NovoCure Ltd ranked in the 95th percentile in terms of potential gain offered. More precisely, our analysis suggests the stock is undervalued by approximately 4108.5% on a DCF basis. As for the metrics that stood out in our discounted cash flow analysis of NovoCure Ltd, consider:
- The compound growth rate in the free cash flow of NovoCure Ltd over the past 1.5 years is 3.93%; that's better than 95.1% of cash flow producing equities in the Healthcare sector, where it is classified.
- The business' balance sheet reveals debt to be 0% of the company's capital (with equity being the remaining amount). Approximately only 2.24% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
- NovoCure Ltd's effective tax rate, as measured by taxes paid relative to net income, is at 0 -- greater than merely 0% of US stocks with positive free cash flow.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | 4006% |
| 1% | 4047% |
| 2% | 4088% |
| 3% | 4129% |
| 4% | 4170% |
| 5% | 4211% |
Want more companies with a valuation profile/forecast similar to that of NovoCure Ltd? See MNKKQ, CYH, AMEH, RDY, and BEAT.
Loading social stream, please wait...